Last reviewed · How we verify
Ceftazidime-avibactam + Sulbactam
A triple-combination antibiotic that inhibits bacterial cell wall synthesis while protecting against resistance mechanisms through beta-lactamase inhibition.
A triple-combination antibiotic that inhibits bacterial cell wall synthesis while protecting against resistance mechanisms through beta-lactamase inhibition. Used for Complicated intra-abdominal infections, Hospital-acquired and ventilator-associated bacterial pneumonia, Complicated urinary tract infections.
At a glance
| Generic name | Ceftazidime-avibactam + Sulbactam |
|---|---|
| Sponsor | National University of Singapore |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination |
| Target | Bacterial penicillin-binding proteins (PBPs); serine beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall cross-linking. Avibactam is a non-beta-lactam beta-lactamase inhibitor that protects ceftazidime from degradation by serine beta-lactamases. Sulbactam is an additional beta-lactamase inhibitor that provides broader coverage against resistant gram-negative organisms, particularly Acinetobacter baumannii.
Approved indications
- Complicated intra-abdominal infections
- Hospital-acquired and ventilator-associated bacterial pneumonia
- Complicated urinary tract infections
- Multidrug-resistant gram-negative bacterial infections
Common side effects
- Diarrhea
- Nausea
- Headache
- Phlebitis at infusion site
- Hypersensitivity reactions
Key clinical trials
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- Optimising TREATment for Severe Gram-Negative Bacterial Infections (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ceftazidime-avibactam + Sulbactam CI brief — competitive landscape report
- Ceftazidime-avibactam + Sulbactam updates RSS · CI watch RSS
- National University of Singapore portfolio CI